Abstract
Abstract
Aims
We investigated the antibacterial efficacy of Umonium38 and Virkon® against Burkholderia pseudomallei, Escherichia coli, Pseudomonas aeruginosa and Methicillin-Resistant Staphylococcus aureus (MRSA) up to 14 days following treatment.
Methods and results
Umonium38 was diluted to 0.5%, 1.0%, 1.5%, 2.0%, 2.5% and 3%, tested against the bacterial strains at various contact times (15 min to 24 h), and incubated for up to 14 days. A minimum concentration of 0.5% Umonium38 with a contact time of 15 min effectively killed approximately 108 CFU/ml of all four bacterial species. No growth was observed on agar plates from day 0 until day 14 for all six concentrations. The bacteria were also inactivated by a 30-minute treatment time using Virkon® 1% solution.
Conclusions
Umonium38 effectively inactivates B. pseudomallei, E. coli, P. aeruginosa and MRSA at a concentration of ≥ 0.5% with a contact time of at least 15 min. The antimicrobial effect of Umonium38 remained for 14 days.
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. World Health Organization. Laboratory biosafety manual, 4th edition: Decontamination and waste management. Available at: https://www.who.int/publications/i/item/9789240011359.
2. Public Health Agency of Canada. Pathogen Safety Data Sheets: Infectious Substances– Pseudomonas spp. Available at: https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/pseudomonas.html.
3. Bodey GP, Bolivar R, Fainstein V, Jadeja L. Infections caused by Pseudomonas aeruginosa. Rev Infect Dis. 1983;5(2):279–313.
4. Bush LM, Vazquez-Pertejo MT. Pseudomonas and Related Infections. MSD Manual. 2022.
5. Weiner LM, Webb AK, Limbago B, et al. Infect Control Hosp Epidemiol. 2016;37(11):1288–301. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014.